Pulse nav.journalClub Débats actifs Tendances Explorer Questions Chercheurs

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Politique de confidentialité

Accueil Explorer nav.journalClub Tendances

⌘+K

May 20, 2026

Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials

Key Points

The central aim is to assess the effectiveness of the quantile-aggregation method for analyzing Alzheimer disease trials.
Evaluated quantile-aggregation method using simulated datasets and publicly available Alzheimer's randomized trial data.
Identified potential advantages of the quantile-aggregation method for data analysis in Alzheimer's trials.

Abstract

This study evaluates the quantile-aggregation method using both simulated data and publicly available Alzheimer disease randomized trial data.

Like

Bookmark

Share

Like

Bookmark

Share

Cite This Study

Flanders et al. (Mon,) studied this question.

synapsesocial.com/papers/6a0d4ec0f03e14405aa99eae https://doi.org/https://doi.org/10.1001/jamaneurol.2026.1240

Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Evaluation of amyloid change as a surrogate for cognitive decline: demonstration in individual‐level data from the A4 study of solanezumab2026 · 1 citations
2Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease2025 · 12 citations
3Trial of Solanezumab in Preclinical Alzheimer’s Disease2023 · 379 citations
4Donanemab in Early Symptomatic Alzheimer Disease2023 · 2,562 citations
5Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis2021 · 180 citations